Patients With MM and CLL Report Blood Cancer Coach App Helpful
A feasibility pilot assessed acceptability of mobile app for symptom management in multiple myeloma and chronic lymphocytic leukemia.
A feasibility pilot assessed acceptability of mobile app for symptom management in multiple myeloma and chronic lymphocytic leukemia.
Treating advanced melanoma with immune checkpoint inhibitors can be safe and effective in patients with concomitant CLL, a study suggests.
New research may explain why patients with CLL tend to respond poorly to COVID-19 vaccination.
Ibrutinib does not improve overall survival in patients with treatment-naïve chronic lymphocytic leukemia at high risk of progression, a phase 3 trial suggests.
Researchers investigated whether adding venetoclax to ibrutinib and obinutuzumab would improve survival and allow for discontinuation of treatment in older patients with CLL.
Researchers sought to determine whether combination therapy with ianalumab and ibrutinib would have efficacy in patients with CLL.
Researchers sought to determine whether patients with CLL/SLL would be able to maintain fixed dosing schedule of venetoclax-based regimens in their treatments.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Researchers sought to determine whether uMRD could determine discontinuation of venetoclax or the addition of ibrutinib in patients with R/R CLL.
Zanubrutinib may produce superior outcomes to ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.